Olivier Keunen

Latest publications

Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

  • NORLUX Neuro-Oncology Laboratory
May 01, 2014
2014 May. Neuro Oncol.16(5):754-6.
By:
  • Pakzad A
  • Obad N
  • Espedal H
  • Stieber D
  • Keunen O
  • Sakariassen PO
  • Niclou SP
  • Bjerkvig R.

The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

  • NORLUX Neuro-Oncology Laboratory
September 01, 2013
2013 Sep. Neuro Oncol.15(9):1200-11. Epub 2013 May 30.
By:
  • Johansson M
  • Oudin A
  • Tiemann K
  • Bernard A
  • Golebiewska A
  • Keunen O
  • Fack F
  • Stieber D
  • Wang B
  • Hedman H
  • Niclou SP.

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis.

  • NORLUX Neuro-Oncology Laboratory
May 01, 2013
2013 May. Acta Neuropathol.125(5):683-98. Epub 2013 Feb 22.
By:
  • Talasila KM
  • Soentgerath A
  • Euskirchen P
  • Rosland GV
  • Wang J
  • Huszthy PC
  • Prestegarden L
  • Skaftnesmo KO
  • Sakariassen PO
  • Eskilsson E
  • Stieber D
  • Keunen O
  • Brekka N
  • Moen I
  • Nigro JM
  • Vintermyr OK
  • Lund-Johansen M
  • Niclou S
  • Mork SJ
  • Enger PO
  • Bjerkvig R
  • Miletic H.

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.

  • NORLUX Neuro-Oncology Laboratory
March 01, 2011
2011 Mar. Proc Natl Acad Sci U S A.108(9):3749-54. Epub 2011 Feb 14.
By:
  • Keunen O
  • Johansson M
  • Oudin A
  • Sanzey M
  • Rahim SA
  • Fack F
  • Thorsen F
  • Taxt T
  • Bartos M
  • Jirik R
  • Miletic H
  • Wang J
  • Stieber D
  • Stuhr L
  • Moen I
  • Rygh CB
  • Bjerkvig R
  • Niclou SP.